A proof-of-concept phase 2a, double-blind, 2-arm trial to investigate efficacy and safety of twice daily delgocitinib cream 20 mg/g compared with cream vehicle during a 16-week treatment period in adult subjects with mild to severe palmoplantar pustulosis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518856-21-00

Acronym

LP0133-2393

Enrollment

Registered

2025-08-01

Start date

2025-08-28

Completion date

Unknown

Last updated

2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild to severe palmoplantar pustulosis

Brief summary

PPPASI-75 at Week 16

Detailed description

PPP-PGA score of 0 or 1 (clear or almost clear) with at least a 2-step improvement from baseline at Week 16., Change in overall number of fresh pustules from baseline to Week 16.

Interventions

DRUGDelgocitinib cream

DRUGCream Vehicle

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PPPASI-75 at Week 16	—

Secondary

Measure	Time frame
PPP-PGA score of 0 or 1 (clear or almost clear) with at least a 2-step improvement from baseline at Week 16., Change in overall number of fresh pustules from baseline to Week 16.	—

Countries

Germany, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026